Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OptiNose Inc OPTN

Healthcare
OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and... see more

Recent & Breaking News (NDAQ:OPTN)

Optinose to Present at the Cantor Virtual Global Healthcare Conference

GlobeNewswire September 14, 2020

Optinose Announces Pricing of Public Offering of Common Stock

GlobeNewswire August 14, 2020

Optinose Announces Proposed Public Offering of Common Stock

GlobeNewswire August 13, 2020

Optinose Reports Second Quarter 2020 Financial Results and Recent Operational Highlights

GlobeNewswire August 4, 2020

Optinose Announces Reporting Date for Second Quarter 2020 Financial Results

GlobeNewswire July 30, 2020

Optinose names Catherine E. Owen as Director

GlobeNewswire July 29, 2020

Optinose Announces XHANCE Co-Promotion Agreement with Kaléo

GlobeNewswire July 8, 2020

Optinose Announces Anti-COVID-19 Product Candidate

GlobeNewswire June 30, 2020

Optinose to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

GlobeNewswire June 22, 2020

Optinose Named a 2020 Best Place to Work by Philadelphia Business Journal

GlobeNewswire June 19, 2020

Optinose to Host its Annual Meeting of Stockholders in Virtual Format

GlobeNewswire May 27, 2020

Optinose to Present at the 2020 Jefferies Virtual Healthcare Conference

GlobeNewswire May 26, 2020

Optinose to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

GlobeNewswire May 14, 2020

Optinose Reports First Quarter 2020 Financial Results and Operational Updates

GlobeNewswire May 7, 2020

Optinose to Report First Quarter 2020 Financial Results and Corporate Updates on May 7, 2020

GlobeNewswire April 30, 2020

Optinose Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Operational Highlights

GlobeNewswire March 5, 2020

Optinose to Report Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates on March 5, 2020

GlobeNewswire February 27, 2020

Optinose Appoints Victor Clavelli as Chief Commercial Officer

GlobeNewswire February 19, 2020

Optinose Announces Peer-Reviewed Publication of the Fourth Major XHANCE Registration Trial

GlobeNewswire December 17, 2019

Optinose to Present at the Piper Jaffray 31st Annual Healthcare Conference

GlobeNewswire November 26, 2019